Identification of lysosome‐targeting drugs with anti‐inflammatory activity as potential invasion inhibitors of treatment resistant HER2 positive cancers

PURPOSE: Most HER2 positive invasive cancers are either intrinsic non-responsive or develop resistance when treated with 1st line HER2 targeting drugs. Both 1st and 2nd line treatments of HER2 positive cancers are aimed at targeting the HER2 receptor directly, thereby strongly limiting the treatment...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cell Oncol (Dordr)
Auteurs principaux: Hansen, Malene Bredahl, Postol, Maria, Tvingsholm, Siri, Nielsen, Inger Ødum, Dietrich, Tiina Naumanen, Puustinen, Pietri, Maeda, Kenji, Dinant, Christoffel, Strauss, Robert, Egan, David, Jäättelä, Marja, Kallunki, Tuula
Format: Artigo
Langue:Inglês
Publié: Springer Netherlands 2021
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8090911/
https://ncbi.nlm.nih.gov/pubmed/33939112
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13402-021-00603-2
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires